Nektar reports Q2 2026 results, details Phase 3 rezpegaldesleukin timelineAug 13Quarterly updateNektar Therapeuticsrezpegaldesleukin
Nektar registers Phase 3 "ZENITH AD-2" trial of rezpegaldesleukin in atopic dermatitisJul 17Trial updateNektar Therapeuticsrezpegaldesleukin
Nektar registers Phase 3 atopic dermatitis trial for rezpegaldesleukinJul 8Trial updateNektar Therapeuticsrezpegaldesleukin
Sign inSign in